In a late-stage trial, Moderna’s flu vaccine elicited a better immune response against all four A and B strains of the influenza virus than traditional flu shots, driving shares up around 6% in early trading.
Moderna’s Flu Vaccine
According to the source, the efficiency of Moderna’s flu vaccination was proved across all age categories, including older persons, and it was found to be safe and tolerable.
In a separate early head-to-head research, Moderna discovered that their shot was equal to or superior than Sanofi’s high-dose flu vaccination.
According to Jefferies analyst Michael Yee, Moderna might utilise this data to file for accelerated clearance of its flu shot in the United States by the end of the year, and the vaccine could be available by the 2024/2025 season.
After failing to achieve the study’s “early-success” criterion, the corporation previously stated that there was insufficient evidence to evaluate if the flu vaccine would be successful.
Company’s shares at $111.45
Moderna also said that it would reduce production of its COVID-19 vaccine, an upgraded version of which was licenced by US regulators this week, to line with lower post-pandemic demand and assist the firm meet its aim of 75%-80% gross margin increase sooner.
Moderna is in talks with its global partners that fill vials and syringes with its messenger RNA-based COVID vaccines to reduce output, according to Stephen Hoge, president of the Massachusetts-based company.
Hoge noted that the downsizing will help Moderna respond to the disease’s endemic phase, which has resulted in lower demand for COVID vaccines as payers reduce orders for the shots.
In August, Moderna anticipated that demand for the vaccine in the United States would reach 50 million to 100 million doses over the autumn season.
According to the Centres for Disease Control and Prevention, approximately 153.8 million COVID shots will be delivered in the United States in 2022.
“Over the past couple of years, we’ve been in pandemic mode producing a billion doses a year,” Hoge said. “We’ve been waiting for the moment when the pandemic was officially behind us that we would need to restructure that manufacturing footprint.”
US Food and Drug Administration
Following approval from the US Food and Drug Administration on Monday, Moderna said that it would begin sending COVID vaccination doses across the country.
According to Hoge, the company has agreements with other countries to deliver its COVID shot, including the United Kingdom, Canada, and Japan, but does not yet have an arrangement with the EU. He also stated that COVID was the focus of Moderna’s production agreement with China.
While Moderna was working urgently to reduce COVID manufacturing, Hoge said that discussions with third-party manufacturers – which will help produce the upcoming respiratory syncytial virus (RSV) and influenza vaccines that investors hope will begin to replace Moderna’s waning COVID revenue – could extend into next year.
“These are relationships that we will need for decades to come,” Hoge said.
Moderna refuses to name the partners, but has previously stated that they include Thermo Fisher Scientific, Sanofi, and Catalent.
Rovi, which has a 10-year contract with Moderna to manufacture mRNA-based medicines, has stated that it does not intend to reduce vaccine production this year.
“The vaccine’s manufacturing runs from June to October and we are already producing it. All the purchase orders are being fulfilled,” a Rovi spokesperson said, referring to the COVID vaccine.
To read our blog on “Moderna & Merck begin late-stage research on cancer vaccine,” click here